Literature DB >> 19264086

Engineered toxins: new therapeutics.

Keith A Foster1.   

Abstract

Clostridial neurotoxins possess discrete structural domains with distinct pharmacological properties. Aspects of neurotoxin function with therapeutic potential include specific neuronal binding, intracellular (cytosolic) delivery of biologically active protein and inhibition of SNARE-mediated secretion. Understanding the structure function relationship of the neurotoxin protein enables the creation of recombinant proteins incorporating select domains of the neurotoxins to produce novel proteins with therapeutic potential in a range of clinical applications.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19264086     DOI： 10.1016/j.toxicon.2009.01.037

Source DB:  PubMed          Journal:  Toxicon        ISSN： 0041-0101            Impact factor:   3.033


  15 in total

1.  SNARE tagging allows stepwise assembly of a multimodular medicinal toxin.

Authors:  Frédéric Darios; Dhevahi Niranjan; Enrico Ferrari; Fan Zhang; Mikhail Soloviev; Andreas Rummel; Hans Bigalke; Jason Suckling; Yuri Ushkaryov; Nikolay Naumenko; Anastasia Shakirzyanova; Rashid Giniatullin; Elizabeth Maywood; Michael Hastings; Thomas Binz; Bazbek Davletov
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

2.  RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin.

Authors:  Pavithra Janardhanan; Charlene M Mello; Bal Ram Singh; Jianlong Lou; James D Marks; Shuowei Cai
Journal:  Talanta       Date:  2013-09-13       Impact factor: 6.057

3.  Substrates and controls for the quantitative detection of active botulinum neurotoxin in protease-containing samples.

Authors:  Karine Bagramyan; Bruce E Kaplan; Luisa W Cheng; Jasmin Strotmeier; Andreas Rummel; Markus Kalkum
Journal:  Anal Chem       Date:  2013-05-22       Impact factor: 6.986

4.  Detection of botulinum neurotoxin serotype A, B, and F proteolytic activity in complex matrices with picomolar to femtomolar sensitivity.

Authors:  F Mark Dunning; Daniel R Ruge; Timothy M Piazza; Larry H Stanker; Füsûn N Zeytin; Ward C Tucker
Journal:  Appl Environ Microbiol       Date:  2012-08-24       Impact factor: 4.792

5.  The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.

Authors:  Alon Ben David; Eran Diamant; Ada Barnea; Osnat Rosen; Amram Torgeman; Ran Zichel
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

6.  A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis.

Authors:  Emmanuel Somm; Nicolas Bonnet; Alberto Martinez; Philip M H Marks; Verity A Cadd; Mark Elliott; Audrey Toulotte; Serge L Ferrari; René Rizzoli; Petra S Hüppi; Elaine Harper; Shlomo Melmed; Richard Jones; Michel L Aubert
Journal:  J Clin Invest       Date:  2012-08-01       Impact factor: 14.808

Review 7.  Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.

Authors:  Sheng Chen
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

Review 8.  Targeted secretion inhibitors-innovative protein therapeutics.

Authors:  Foster Keith; Chaddock John
Journal:  Toxins (Basel)       Date:  2010-12-03       Impact factor: 4.546

Review 9.  Towards new uses of botulinum toxin as a novel therapeutic tool.

Authors:  Andy Pickett; Karen Perrow
Journal:  Toxins (Basel)       Date:  2011-01-12       Impact factor: 4.546

10.  Recombinant L-HN Fusion Antigen Derived from the L and HN Domains of Botulinum Neurotoxin B Stimulates a Protective Antibody Response Against Active Neurotoxin.

Authors:  Zhen Li; Jian-Sheng Lu; Shan Liu; Rong Wang; Qing Xu; Yun-Zhou Yu; Zhi-Xin Yang
Journal:  Neurotox Res       Date:  2021-02-22       Impact factor: 3.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.